Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery a...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
1997
|
| Schriftenreihe: | Cancer Drug Discovery and Development
|
| Schlagworte: | |
| Online-Zugang: | DE-355 URL des Erstveröffentlichers |
| Zusammenfassung: | Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery and approval. The expert contributors focus on using in vivo and in vitro methods preclinically to identify molecules of interest, detailing the targets and criteria for success in each type of testing, and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval offers cancer researchers an authoritative survey rich in essential insight into the means and methods of cancer drug discovery and approval. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field |
| Beschreibung: | 1 Online-Ressource (XII, 311 p. 39 illus) |
| ISBN: | 9781461581529 |
| DOI: | 10.1007/978-1-4615-8152-9 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145060 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1997 xx o|||| 00||| eng d | ||
| 020 | |a 9781461581529 |9 978-1-4615-8152-9 | ||
| 024 | 7 | |a 10.1007/978-1-4615-8152-9 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-8152-9 | ||
| 035 | |a (OCoLC)1119021427 | ||
| 035 | |a (DE-599)BVBBV046145060 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 615 |2 23 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Anticancer Drug Development Guide |b Preclinical Screening, Clinical Trials, and Approval |c edited by Beverly A. Teicher |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 1997 | |
| 300 | |a 1 Online-Ressource (XII, 311 p. 39 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Drug Discovery and Development | |
| 520 | |a Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery and approval. The expert contributors focus on using in vivo and in vitro methods preclinically to identify molecules of interest, detailing the targets and criteria for success in each type of testing, and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval offers cancer researchers an authoritative survey rich in essential insight into the means and methods of cancer drug discovery and approval. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field | ||
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Teicher, Beverly A. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461581543 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461581536 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780896034617 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-8152-9 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031525245 | |
| 966 | e | |u https://doi.org/10.1007/978-1-4615-8152-9 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1823607507869761536 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Teicher, Beverly A. |
| author2_role | edt |
| author2_variant | b a t ba bat |
| author_facet | Teicher, Beverly A. |
| building | Verbundindex |
| bvnumber | BV046145060 |
| classification_rvk | XI 7000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-8152-9 (OCoLC)1119021427 (DE-599)BVBBV046145060 |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-8152-9 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV046145060</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1997 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461581529</subfield><subfield code="9">978-1-4615-8152-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-8152-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-8152-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119021427</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145060</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticancer Drug Development Guide</subfield><subfield code="b">Preclinical Screening, Clinical Trials, and Approval</subfield><subfield code="c">edited by Beverly A. Teicher</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 311 p. 39 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Drug Discovery and Development</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery and approval. The expert contributors focus on using in vivo and in vitro methods preclinically to identify molecules of interest, detailing the targets and criteria for success in each type of testing, and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval offers cancer researchers an authoritative survey rich in essential insight into the means and methods of cancer drug discovery and approval. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teicher, Beverly A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461581543</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461581536</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780896034617</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-8152-9</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525245</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-8152-9</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046145060 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-09T19:00:43Z |
| institution | BVB |
| isbn | 9781461581529 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525245 |
| oclc_num | 1119021427 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 311 p. 39 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1997 |
| publishDateSearch | 1997 |
| publishDateSort | 1997 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Cancer Drug Discovery and Development |
| spelling | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval edited by Beverly A. Teicher Totowa, NJ Humana Press 1997 1 Online-Ressource (XII, 311 p. 39 illus) txt rdacontent c rdamedia cr rdacarrier Cancer Drug Discovery and Development Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery and approval. The expert contributors focus on using in vivo and in vitro methods preclinically to identify molecules of interest, detailing the targets and criteria for success in each type of testing, and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval offers cancer researchers an authoritative survey rich in essential insight into the means and methods of cancer drug discovery and approval. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field Pharmacology/Toxicology Oncology Toxicology Oncology Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Cytostatikum (DE-588)4068347-3 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Teicher, Beverly A. edt Erscheint auch als Druck-Ausgabe 9781461581543 Erscheint auch als Druck-Ausgabe 9781461581536 Erscheint auch als Druck-Ausgabe 9780896034617 https://doi.org/10.1007/978-1-4615-8152-9 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval Pharmacology/Toxicology Oncology Toxicology Oncology Arzneimittelentwicklung (DE-588)4143176-5 gnd Cytostatikum (DE-588)4068347-3 gnd |
| subject_GND | (DE-588)4143176-5 (DE-588)4068347-3 (DE-588)4143413-4 |
| title | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval |
| title_auth | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval |
| title_exact_search | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval |
| title_full | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval edited by Beverly A. Teicher |
| title_fullStr | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval edited by Beverly A. Teicher |
| title_full_unstemmed | Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval edited by Beverly A. Teicher |
| title_short | Anticancer Drug Development Guide |
| title_sort | anticancer drug development guide preclinical screening clinical trials and approval |
| title_sub | Preclinical Screening, Clinical Trials, and Approval |
| topic | Pharmacology/Toxicology Oncology Toxicology Oncology Arzneimittelentwicklung (DE-588)4143176-5 gnd Cytostatikum (DE-588)4068347-3 gnd |
| topic_facet | Pharmacology/Toxicology Oncology Toxicology Oncology Arzneimittelentwicklung Cytostatikum Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-8152-9 |
| work_keys_str_mv | AT teicherbeverlya anticancerdrugdevelopmentguidepreclinicalscreeningclinicaltrialsandapproval |